IL6 and small cell lung carcinoma: Prophylactic use of an anti-IL-6 mAb, which is currently used in the management of CRS, is being trialled with CD3xPSMA BiTE for small cell lung cancer (NCT04496674) and may allow an increased maximum tolerated dose of the BiTE [85].